Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients.

Published in:

Pharmacology Research & Perspectives, 2022, v. 10, n. 6, p. 1, doi. 10.1002/prp2.1015

By:

• Kos, Renate;
• Neerincx, Anne H.;
• Fenn, Dominic W.;
• Brinkman, Paul;
• Lub, Rianne;
• Vonk, Steffie E. M.;
• Roukema, Jolt;
• Reijers, Monique H.;
• Terheggen‐Lagro, Suzanne W. J.;
• Altenburg, Josje;
• Majoor, Christof J.;
• Bos, Lieuwe D.;
• Haarman, Eric G.;
• Maitland‐van der Zee, Anke H.

Publication type:

Article